Stockwinners Market Radar for May 16, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:26 EDT MorphoSys confirms primary endpoint of L-MIND study was met - MorphoSys AG announced results from the primary analysis of the ongoing single-arm phase 2 clinical trial known as L-MIND. The results overall confirm earlier reported interim data from this trial. L-MIND is designed to investigate the antibody tafasitamab in combination with lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma who are ineligible for high-dose chemotherapy and autologous stem cell transplantation. The data reported today included 80 patients enrolled into the trial who had received tafasitamab and lenalidomide and had been followed-up as per protocol for at least one year. Efficacy results in this update are based on response rates assessed by an independent review committee for all 80 patients.

18:57 EDT Zendesk CEO: We help companies provide great customer service - In an interview on CNBC's Mad Money, Zendesk CEO Mikkel Svane said: Customer expectations have changed significantly over the last 10 years... We help companies provide great customer service... Every business is moving to AWS.

18:46 EDT United Continental granted tentative permission to fly to Tokyo - The U.S. Department of Transportation has tentatively granted United Airlines a total of four daily nonstop flights to Tokyo Haneda Airport. The slots will be allocated for flights from United's hubs at Newark Airport, Chicago O'Hare, Washington Dulles and Los Angeles International Airport. Pending completion of an aviation agreement between the U.S. and Japanese governments later this year, the flights are expected to begin service by the summer of 2020.

18:33 EDT Fluor confirms appointment of Carlos Hernandez as CEO - Fluor announced that its board of directors has confirmed the appointment of Carlos Hernandez as CEO and named him a member of the board of the company. Hernandez was named as Fluor's interim CEO on May 1, in line with the company's established succession plan following David Seaton stepping down. The board of directors also named John Reynolds as the new chief legal officer of Fluor.

18:00 EDT IDACORP names Richard J. Dahl board chairman - IDACORP announced the appointment of Richard J. Dahl to serve as the new independent chairman of the boards of directors of IDACORP and its wholly owned subsidiary, Idaho Power. Dahl will also serve as chairman of the board of directors' corporate governance and nominating committees, to succeed Robert A. Tinstman in these roles. Dahl has served as a director of IDACORP and Idaho Power since 2008 and has been chair of the board of directors' audit committee since 2009. Dahl is the former President and Chief Executive Officer and director of James Campbell Company LLC.

17:56 EDT Nvidia pares afterhours gains to 1.5% after pulling FY19 guidance

17:51 EDT Nvidia CFO says not planning to give FY19 guidance at this point - Says drivers are still working.

17:49 EDT Ra Medical files complaint in U.S. court against Strata Skin Chairman Uri Geiger - Ra Medical said in a statement: "Ra Medical Systems (RMED) filed a complaint in the United States District Court for the Southern District of California alleging Mr. Uri Geiger, Chairman of Strata Skin Sciences (SSKN), and managing partner of Accelmed, undertook a campaign of false, misleading, and disparaging statements to Ra Medical's financial partners and potential investors before, during, and after Ra Medical's initial public offering.Ra Medical believes these false statements constituted intentional interference with Ra Medical's contractual relations and prospective economic relations, as well as trade libel. In addition, Ra Medical alleges that the statements breached the non-disparagement provision of a prior settlement agreement to which Strata was expressly bound. Ra Medical supports innovation and competition in the medical device market. To that end, Ra Medical is focused on commercializing excimer laser systems to treat vascular and dermatological diseases. Strata's actions did nothing to advance innovation or competition. Instead, they appear to be a deliberate attempt to derail Ra Medical's mission by limiting our access to the capital markets, as well as by harming our brand and reputation. As a result, we believe that this lawsuit is necessary to protect our interests and those of our stockholders, our physician customers and their patients. Ra Medical is seeking a declaration that Strata breached the settlement agreement, interfered with contractual relations and with prospective economic relations, and committed trade libel. Ra Medical is seeking monetary damages, including our costs and legal fees as provided by the settlement agreement, and such further relief which as court deems just and proper," said the company.

17:38 EDT Nvidia says Q1 had 'significant positives' for Data Center Group - Says some clients have increased spending while others have paused. Comments from Q1 earnings call.

17:33 EDT Ensco Rowan awarded $180M in damages by arbitration tribunal - Ensco Rowan has been awarded by an arbitration tribunal $180M in damages in its proceedings against Samsung Heavy Industries, a shipyard in South Korea. The company will be claiming interest on this amount and costs incurred in connection with this matter. In April 2016, the company initiated arbitration proceedings in London against SHI for the losses incurred in connection with a drilling services agreement for ENSCO DS-5 that was voided by a customer. In January 2018, the arbitration tribunal issued an award on liability fully in EnscoRowan's favor, and the arbitral hearing on damages took place in 1Q19. SHI may apply to the English High Court for leave to appeal this award within 28 days from date of award. There can be no assurance when the company will be paid all or any portion of the damages awarded or any related interest or costs.

17:20 EDT PulteGroup announces $500M share buyback increase - PulteGroup announced that its board has approved an increase of $500M to its share repurchase authorization. As of May 15, 2019, there was $262M remaining under the current plan, so the company's share repurchase authorization now totals approximately $762M. PulteGroup also announced that it will commence a cash tender offer for $300 million of its 4.250% senior notes due 2021.

17:00 EDT Range Resources names Dennis Degner COO - Range Resources announced that Dennis Degner was appointed to the position of Senior Vice President - Chief Operating Officer, effective immediately. Degner has been with Range for nine years, most recently as Senior Vice President of Operations where he managed operations and marketing across the entire company. Previously at Range, he led the company's Appalachia Division in Pennsylvania. "We are very excited to welcome Dennis into this role and are confident that he will continue to be instrumental in Range's success, as we deliver on our plan to generate sustainable free cash flow with industry-leading operational efficiency and a strict focus on capital discipline," said Jeff Ventura, Range's CEO and President.

16:39 EDT Wex officer Hilary Rapkin sells almost $223K in company shares - Wex officer Hilary Rapkin disclosed in a filing that she had sold 1,096 shares of company stock at an average price of $203.27 per share on May 16. The total transaction value of the sale was $222,784.

16:37 EDT Baidu reports Q1 DAUs reached 174M, up 28% y/y - Baidu App daily active users in March 2019 reached 174M, growing 28% year over year. Haokan DAUs in March reached 22M, growing 768% year over year and 16% sequentially. Baidu continues to expand its content ecosystem to provide users with native-app like experience for search and feed: 1) Baijiahao, Baidu feed's content network, grew to 2.1M publisher accounts in March, and 2) Baidu Smart Mini Program, launched in July 2018, saw its monthly active users in March reach 181M, growing 23% sequentially. Baidu connected 1.5M out-of-home digital screens in 362 cities across 31 provinces to its ad partner network in March, leveraging its technology and online advertising expertise to equip brands with broader reach and more options to deliver omni-marketing campaigns.

16:32 EDT Butterfield COO Daniel Frumkin to step down - Butterfield announced that Daniel Frumkin, Group Chief Operating Officer, has informed the bank of his decision to step down from his post, effective immediately. Frumkin has agreed to continue to be available to the Bank's senior management to ensure a seamless transition. As a result of this departure, Michael Neff, Managing Director Bermuda, will lead the company's international trust business and Richard Saunders, Managing Director Channel Islands, will assume responsibility for international corporate banking. Michael McWatt, Managing Director Cayman Islands, will manage operations for Bermuda and Cayman. Finally, Michael Schrum, Group Chief Financial Officer, will oversee corporate development and information technology.

16:31 EDT Ecology & Environment receives Nasdaq determination letter - On May 13, 2019, Ecology and Environment Inc. received, as expected, a formal determination letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that the company did not meet the terms of the exception that was previously granted by the Nasdaq Staff in order to allow the company to regain compliance with Nasdaq Listing Rule 5250c1. As previously reported, the company is not in compliance with the Rule because it has not filed its Annual Report on Form 10-K for the fiscal year ended July 31, 2018 and its Quarterly Reports on Form 10-Q for the periods ended October 27, 2018 and January 26, 2019. The Letter provides that, as the company did not regain compliance with the Rule prior to May 13, 2019, the company's common stock would be subject to delisting, unless the company timely requests a hearing before the Nasdaq hearings panel. The company intends to timely request a hearing before the Panel. At the hearing, the company will present its plan for regaining compliance with the Rule, and request continued listing pending its return to compliance. The hearing request automatically stays the delisting for a period of 15 calendar days from the date of the request. In addition, in connection with its request for a hearing, the company will request that the Panel continue the stay of delisting until the conclusion of the hearing process. The Panel has the discretion to grant the company an extension of time within which to regain compliance with the Rule for a period not to exceed 360 days from the original due date for the first late filing. There is no assurance that the Panel will grant the company's request for a stay of delisting pending the hearing or its request to extend the time within which to regain compliance with the Rule and for continued listing. Although the company is working diligently and currently anticipates it will submit its Delinquent Filings to the Securities and Exchange Commission and regain compliance with the Rule by the end of May 2019, it cannot provide any assurances that such anticipated date will be met.

16:27 EDT Bonanza Creek says lenders increase borrowing base to to $375M from $350M - Bonanza Creek Energy announced that the lenders under its senior secured credit facility have concluded their semi-annual redetermination, resulting in an increase in the borrowing base to $375M from $350M. While the bank syndicate fully subscribed to the new borrowing base, the Company chose to hold the aggregate elected commitments at $350M. As of March 31, the company had $65M drawn on the facility and held approximately $33M in cash. Eric Greager, Chief Executive Officer, commented, "We are pleased with the outcome of our spring redetermination and appreciate the support of our bank group. We are committed to maintaining a strong balance sheet, disciplined execution, and increasing shareholder value."

16:22 EDT Kilroy Realty raises quarterly dividend by 6.6% to 48.5c per share - The dividend is payable on July 17, 2019 to stockholders of record on June 28, 2019.

16:18 EDT Ferroglobe CFO Phillip Murnane to resign - Phillip Murnane, the company's CFO, has given notice of his intention to resign, effective July 29, 2019. Jose Maria Calvo-Sotelo, who has been the deputy CFO and EVP of Corporate Development since 2016, will continue to work alongside Mr. Murnane during the transition.

16:14 EDT NVR's Preiser sells 520 common shares - In a regulatory filing, NVR director David A. Preiser disclosed the sale of 520 common shares of the company at a price of $3,310.85 per share.

16:07 EDT Axovant announces dosing of first patient in AXO-AAV-GM1 study - Axovant Gene Therapies announced dosing of the first patient in a clinical study of AXO-AAV-GM1, an investigational gene therapy for the treatment of GM1 gangliosidosis. To date, the patient has experienced no complications related to the intravenous administration of the vector and continues to be followed by physicians. There are currently no approved treatments for GM1 gangliosidosis. Axovant expects initial data from the AXO-AAV-GM1 clinical program in the second half of 2019, as well as continued enrollment of patients in this program throughout 2019.

16:05 EDT Pinterest reports Q1 global MAUs up 22% at 291M - Reports Q1 global ARPU up 26% at 73c.

16:03 EDT Applied Materials up 3.2% after reporting Q2 earnings, giving Q3 guidance

15:50 EDT Rubicon Project falls after report Amazon near buying ad tech asset - Shares of advertising technology firm Rubicon Project (RUBI) are falling in late day trading after a Bloomberg report that said Amazon (AMZN) is near to buying the ad-serving technology of bankrupt company Sizmek. According to the report, Sizmek has been selling off businesses as part of bankruptcy proceedings it initiated in March. SIZMEK'S AD SERVER: According to the Bloomberg story, Sizmek's Ad Server "helps advertisers place spots around the internet and measure their effectiveness, competes directly with Google's (GOOG, GOOGL) Marketing Platform, formerly known as DoubleClick." RUBICON BUSINESS: Rubicon describes itself as a technology company automating the buying and selling of advertising. Rubicon Project says on its website that it allows premium publishers to solve the complexity and stay autonomous with "Prebid, the open-source standard for header bidding. Future proof for tomorrow's formats and tech." PRICE ACTION: Shares of Rubicon Project are down 4%to $6.13 per share, while Amazon and Google are up almost 1.8% and 1.3%, respectively.

15:16 EDT Boeing says completed development of updated software for 737 MAX - Boeing announced that it has completed development of the updated software for the 737 MAX, along with associated simulator testing and the company's engineering test flight. "To date, Boeing has flown the 737 MAX with updated MCAS software for more than 360 hours on 207 flights," the company stated in a post to its corporate website. Boeing is now providing additional information to address Federal Aviation Administration requests that include detail on how pilots interact with the airplane controls and displays in different flight scenarios. Once the requests are addressed, Boeing will work with the FAA to schedule its certification test flight and submit final certification documentation. "With safety as our clear priority, we have completed all of the engineering test flights for the software update and are preparing for the final certification flight. We're committed to providing the FAA and global regulators all the information they need, and to getting it right. We're making clear and steady progress and are confident that the 737 MAX with updated MCAS software will be one of the safest airplanes ever to fly. The accidents have only intensified our commitment to our values, including safety, quality and integrity, because we know lives depend on what we do," said Boeing Chairman, President and CEO Dennis Muilenburg.

15:10 EDT CannTrust appoints Len Walt Chief Medical Officer - CannTrust Holdings announced the appointment of Dr. Len Walt to the newly created position of Chief Medical Officer. Most recently Dr. Walt held the position of VP and Head of Medical Affairs at Sobi Inc., where he led their North American medical and scientific operations.

15:05 EDT Cummins says Columbus Indiana hub for the Electrified Power Business - Cummins along with the Governor of Indiana and the Mayors of Columbus, Greenwood and Indianapolis, announced plans to expand its presence along the "Cummins Corridor" with new building projects and investment along I-65 in its global headquarters in Columbus, in Greenwood and in Indianapolis, Indiana. Over the long-term the company projects continued global growth, including in Indiana, where it currently employs over 10,000 people. To address future growth expectations, Cummins is continuing to execute on its plans to create work environments across the state that foster growth and help attract and retain top talent. As part of this plan, Cummins announced that Columbus will be the primary North American manufacturing center and corporate hub for the Electrified Power Business with a significant presence at the Columbus Engine Plant. It will also locate a new office building to serve as a hub for digital and information technology employees in Greenwood. And in Indianapolis, the company announced that it has renovated space at the Salesforce tower and is in the process of building out additional space at its Distribution Business headquarters in downtown Indianapolis. "I am pleased to partner with the Governor and city and community leaders to plan for future growth across Indiana so Cummins can continue to have a positive impact on the economic and social vibrancy of our Indiana communities for years to come," said Tom Linebarger, Chairman and CEO, Cummins Inc.

15:00 EDT IAMGold jumps 9% after Bloomberg says company considering sale

14:24 EDT SuperCom announces new electronic monitoring contract in Tennessee - SuperCom announced that the company has secured a new contract to provide its PureSecurity Electronic Monitoring GPS offender tracking and monitoring solutions to "a longstanding, established service provider" for the Judicial and Corrections market across the state of Tennessee. "This new partner is an established EM service provider with an extensive, longstanding track record in the market. SuperCom expects to start generating recurring revenues from this contract in the coming weeks," the company stated.

13:43 EDT Twitter is revamping TweetDeck with ability to add GIFs, threads, image tagging - After putting out a poll yesterday on Twitter asking, "If we could wave a magic wand, what functionality would you most like to see added to TweetDeck?, TweetDeck said on Thursday, "Guess what? You're in luck! As of today we're testing a new way of Tweeting, now with the ability to add GIFs, threads, polls, emoji AND image tagging via TweetDeck." Reference Link

13:12 EDT Skechers expands board to ten with appointment of Katherine Blair - Skechers USA announced that the company has named Katherine Blair to its board of directors as an independent member. The appointment brings the total number of directors to ten, including six independent members. Blair has practiced law for over 20 years and is a partner at Manatt, Phelps & Phillips in Los Angeles. Including this appointment, the Skechers Board of Directors is comprised of Skechers founder, chairman and CEO Robert Greenberg, Skechers president Michael Greenberg, Skechers COO David Weinberg, Skechers SVP Jeffrey Greenberg, as well as independent members Katherine Blair, Morton Erlich, Geyer Kosinski, Richard Rappaport, Richard Siskind, and Thomas Walsh.

13:04 EDT SoCalGas wins approval from CPUC to proceed with dairy biomethane projects - Southern California Gas Co., a subsidiary of Sempra Energy, announced the utility received approval from the California Public Utilities Commission to begin the next phase in construction of four new dairy biomethane projects in California. Last week, the CPUC approved the contracts signed between SoCalGas and the developers of the four projects for the construction of infrastructure that will connect each biomethane facility to the SoCalGas pipeline system. This approval now allows SoCalGas to move forward, starting with the design and engineering phase. When completed, biogas from anaerobic digesters at 35 dairies will be collected and then cleaned to produce pipeline-quality renewable natural gas. The new projects represent four of six pilot projects in the San Joaquin and Sacramento Valleys selected by the CPUC, the Air Resources Board and the Department of Food and Agriculture in December 2018. These new dairy biomethane facilities will significantly reduce greenhouse gas emissions by harnessing methane emissions from dairy digesters and converting that energy into renewable natural gas which can be used to heat homes and businesses, for cooking and to fuel trucks and buses. The facilities are targeted to be completed by December 2020 and combined, will have the ability to produce enough renewable natural gas to fuel close to 40,000 homes each year. Today, there are about 37 dairy methane capture projects either operating or in development, and experts estimate there could be as many as 120 projects funded and operating in the next five years. In addition, as the state seeks to divert organic waste from landfills and capture emissions from wastewater treatment plants, more locally produced RNG will become available.

13:03 EDT Borqs Technologies says Chongqing Youtong to own 9.9% stake after investment - Borqs Technologies reported that the company has completed a financing transaction via the private sale of ordinary shares to the Chongqing City Youtong Equity Investment Fund, by which Chongqing Youtong will own approximately 9.9% of the company's outstanding shares as a result. The transaction involves the sale of 3,734,283 shares at the fixed price of $3.713 per share for a total of $13,865,393. Of the total transaction, 75% was completed as of May 16. The remainder 25% will be issued in exchange for other assets of Chongqing Youtong to be valuated and completed six months after the first closing. The shares will be unregistered and subject to lock up provisions for one year. The company intends to set up a R&D center in Chongqing in the near term which will also serve as Borqs' China head office, and may establish manufacturing facilities in the future.

12:44 EDT BAE Systems names Tom Arseneault president and COO - BAE Systems announced that Tom Arseneault has been named president and COO of BAE Systems, Inc. and appointed to the BAE Systems, Inc. Board of Directors. Jerry DeMuro will continue to serve as CEO for the U.S.-headquartered organization. For several years, Arseneault has served as COO, responsible for operational performance and delivering key business objectives across the enterprise, to include leading the Inc. Strategy and Corporate Development team. As president & COO, his responsibilities will expand to include functional leadership of the BAE Systems, Inc. organization.

12:22 EDT RegeneRx partner receives patent for new ophthalmic formulation of Tbeta4 - RegeneRx Biopharmaceuticals announced that its U.S. joint venture partner and Pan Asian licensee, GtreeBNT, has been granted a new U.S. patent for a method of preventing or treating dry eye syndrome by administering Tbeta4 with non-active ingredients to provide improved pharmacodynamics. Tbeta4 is the active component of RGN-259, currently in separate phase 3 clinical trials for dry eye syndrome and neurotrophic keratitis. The expiry of this new patent is 2035. "We are pleased that Gtree has been granted another patent related to Tbeta4 in the ophthalmic field emanating from its comprehensive development of RGN-259, our sterile, preservative-free eye drop solution. New intellectual property, such as patents and know-how developed under our licenses to Gtree and our U.S. joint venture, ReGenTree LLC, expands and extends the IP portfolio underlying these licenses," stated J.J. Finkelstein, president and CEO. RGN-259 is currently the subject of a 700-patient phase 3 clinical trial in the U.S, ARISE-3.

12:08 EDT Incyte announces abstracts featuring genomic profiling data for ASCO - Incyte announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology Annual Meeting, to be held from May 31-June 4, in Chicago, Illinois; and the 24th Congress of the European Hematology Association, to be held June 13-16, in Amsterdam, the Netherlands. Abstracts accepted for presentation at ASCO feature genomic profiling data from Incyte's ongoing Phase 2 FIGHT-202 trial evaluating its selective fibroblast growth factor receptor inhibitor, pemigatinib, in patients with cholangiocarcinoma, as well as efficacy and safety data from the Novartis-sponsored GEOMETRY mono-1 trial of capmatinib, the investigational selective MET inhibitor licensed to Novartis by Incyte. Additionally, data to be presented at EHA will showcase the continued study of Incyte's JAK1/JAK2 inhibitor, ruxolitinib, in myeloproliferative neoplasms. "Our presence at ASCO and EHA illustrates Incyte's ongoing commitment to discovering and developing therapeutic options that address significant unmet medical needs for patients," said Steven Stein, M.D., Chief Medical Officer, Incyte. "We are pleased to highlight new data on two investigational medicines - pemigatinib and capmatinib - that were discovered by Incyte scientists and for which we anticipate applications for initial U.S. regulatory approvals later this year, as well as data that furthers our understanding of the treatment of MPNs."

12:00 EDT Inphi falls -13.0% - Inphi is down -13.0%, or -$6.67 to $44.80.

12:00 EDT Roan Resources falls -14.2% - Roan Resources is down -14.2%, or -60c to $3.60.

12:00 EDT Kemet rises 15.8% - Kemet is up 15.8%, or $2.62 to $19.20.

11:14 EDT Marsh & McLennan raises quarterly dividend to 45.5c per share from 41.5c - Marsh & McLennan held its annual meeting of stockholders. During the meeting, the board increased the quarterly cash dividend from 41.5c to 45.5c per share on outstanding common stock, payable on August 15, to stockholders of record on July 11.

11:05 EDT Corning tells Reuters does not see 'material' financial impact from Huawei ban - Corning issued a statement to Reuters stating that it does not believe that the U.S. order banning sales to Huawei "will have a material impact on Corning's overall financial performance." The company said it is "confident that our optical communications business segment will remain on track to deliver on its goal of $5B in 2020 sales," according to Reuters. Corning added that it will "continue to fully comply with all U.S. trade regulations," Reuters said.

10:58 EDT NTSB says Tesla autopilot engaged at time of fatal crash - The National Transportation Safety Board has issued its preliminary report for its ongoing investigation of the fatal, March 1, 2019, highway crash near Delray Beach, Florida that involved a 2018 Tesla Model 3 vehicle and an International truck-tractor in combination with a semitrailer. The report states: "According to surveillance video in the area and forward-facing video from the Tesla, the combination vehicle slowed as it crossed the southbound lanes, blocking the Tesla's path. The Tesla struck the left side of the semitrailer. The roof of the Tesla was sheared off as the vehicle underrode the semitrailer and continued south... The 50-year-old male Tesla driver died as a result of the crash. The 45-year-old male driver of the combination vehicle was uninjured...Preliminary data from the vehicle show that the Tesla's Autopilot system-an advanced driver assistance system that provides both longitudinal and lateral control over vehicle motion-was active at the time of the crash.1 The driver engaged the Autopilot about 10 seconds before the collision. From less than 8 seconds before the crash to the time of impact, the vehicle did not detect the driver's hands on the steering wheel." Reference Link

10:00 EDT NeoPhotonics falls -10.3% - NeoPhotonics is down -10.3%, or -59c to $5.13.

10:00 EDT Dillard's falls -11.5% - Dillard's is down -11.5%, or -$7.32 to $56.07.

10:00 EDT Kemet rises 11.0% - Kemet is up 11.0%, or $1.82 to $18.40.

09:47 EDT Dillard's falls -7.6% - Dillard's is down -7.6%, or -$4.81 to $58.58.

09:47 EDT NeoPhotonics falls -12.6% - NeoPhotonics is down -12.6%, or -72c to $5.00.

09:47 EDT Kemet rises 10.4% - Kemet is up 10.4%, or $1.72 to $18.30.

09:32 EDT Medtronic announces global launch of Telescope Guide Extension Catheter - Medtronic announced its entrance into the guide extension catheter market with the global launch of the Telescope Guide Extension Catheter, which it identifies as a newly designed catheter used to provide additional backup support and access to distal lesions. "Before bringing this important technology to market, we collaborated with more than 700 interventional cardiologists to ensure Telescope was addressing unmet needs in complex PCI," said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic.

09:23 EDT Pointer Telocation receives contract in Brazil with $6.5M ceiling - Pointer Telocation has received a large fleet management contract in Brazil valued at up to $6.5M over five years. Installations are expected to be completed in Q3 to support services ramp in Q4 based on Pointer's telematic services and technology solutions for Fleet Management.

09:16 EDT Amira Nature Foods announces departure of CFO Varun Sethi - Amira Nature Foods announced the hiring of Brio Financial Group as financial consultants to the company, to replace the current CFO Varun Sethi, whose last day with the company will be 30 June 2019. The company has hired Brio Financial Group in connection with the company's effort to westernize its corporate finance and executive team while the company focuses on the international growth of its brands. Sethi, who has served as CFO since August 2017, has agreed to assist the company in the orderly transition of his CFO responsibilities. His departure is not based on any disagreement with the company's accounting principles, practices or financial statement disclosures.

09:16 EDT Chubb raises annual dividend 3% to $3.00 per share - The company's Board of Directors declared that shareholders of record at the close of business on June 21 will be entitled to payment of the first installment of 75c per share on July 12.

09:15 EDT Maxar selected by NASA study future space-based communication systems - Maxar Technologies announced that it has been selected by NASA to study future systems "that could revolutionize NASA's space-based communications architecture through innovative technologies and commercial partnerships." The future architecture would be used for scientific and human exploration missions in Earth orbit, at the Moon, and throughout the solar system beginning in the mid-2020s.

09:12 EDT Adverum Biotechnologies announces lift of clinical hold on ADVM-022 - Adverum Biotechnologies announced that the FDA has lifted the clinical hold on ADVM-022 for the second cohort in the company's OPTIC Phase 1 trial for wet age-related macular degeneration, or wet AMD, allowing dose escalation. This dose would be three times higher than the dose evaluated in the first cohort. However, based on the robust preliminary anatomical response observed to date in the first cohort, Adverum will begin dosing the second cohort at a lower dose three times lower than the dose used in the first cohort. The dosing of patients in this second cohort is expected to begin in June. Adverum believes that ADVM-022 at a dose of 6 x 10^11 vg/eye has demonstrated the potential to provide sustained efficacy following a single intravitreal injection. As previously announced, the independent data monitoring committee unanimously voted to proceed with dose escalation per protocol following their review of the safety data from the first cohort. To date, no patient in the first cohort has experienced a serious adverse event, with the first patient completing the 24-week assessment. While the FDA has lifted the clinical hold on the second cohort, ADVM-022 remains on partial clinical hold for dosing patients in the third cohort, with the highest dose. Adverum currently does not plan to dose at this highest level, based on the preliminary anatomical response observed in the first cohort of patients. Adverum will continue to work closely with the FDA to resolve the remaining CMC comments.

09:12 EDT Pulmatrix CEO Dr. Robert Clarke steps down, Ted Raad to succeed - Pulmatrix announces that Dr. Robert Clarke has stepped down as CEO. Ted Raad will immediately transition from his current role as Chief Business Officer to that of CEO and member of the Pulmatrix Board of Directors. In order to ensure a smooth transition, Dr. Clarke will continue as an advisor to the Board of Directors and company management through August 14. Raad joined Pulmatrix in 2017 as Chief Business Officer to provide strategic business guidance and lead all business development efforts. Raad brings more than 20 years of experience, including executive leadership roles at Option Care and Sunovion Pharmaceuticals.

09:09 EDT HomeStreet urges shareholders to vote for director nominees - The Board of Directors of HomeStreet sent a letter to shareholders in connection with the Company's upcoming 2019 Annual Meeting of Shareholders. The company said, "As we approach the 2019 Annual Meeting, you will face an important choice that could impact the future of HomeStreet and the value of your investment in the Company: supporting HomeStreet's highly-qualified and proven director nominees, including CEO and Chairman Mark Mason, or voting for two dissident candidates put forward by activist hedge fund Roaring Blue Lion Capital Management. Since the 2018 Annual Meeting of Shareholders, we have engaged extensively with our shareholders and have worked to translate their feedback into positive and constructive action. We have also reoriented our strategy and are executing against a plan to drive near- and long-term value creation...HomeStreet is executing a plan focused on improving efficiency and profitability while becoming a leading West Coast regional bank - and we are seeing results. The components of our strategic plan include: Focus on Commercial & Consumer Banking...Exiting our Large-Scale Home Loan Center-Based Mortgage Banking Business...We have made significant progress to date: In the years since our IPO the Company has continuously grown the key metrics that drive value...We have invested significantly in our commercial banking segment to diversify our net income, and we have built a powerful Commercial and Consumer Banking platform in highly attractive markets...We are focused on executing the Home Loan Center-Based Mortgage Origination Business and MSR Sale and concentrating on the Commercial and Consumer Banking Business...HomeStreet is always open to engaging with our shareholders and considering ideas that may drive shareholder value creation - and, following the 2018 Annual Meeting, the Board has been working to ensure that shareholders have a direct line of communication with their directors...We have not just listened - we have acted...HomeStreet's Board is comprised of highly-qualified directors who are proven leaders with diverse expertise across the key areas we believe are critical to the success of the Company...Our directors up for re-election at the 2019 Annual Meeting are integral members of our Board...Despite the Board's repeated attempts to engage with Roaring Blue Lion in productive discussions, its principal, Charles W. Griege, Jr., remains resolute in pursuing a disruptive and costly contested election. Based on its initial assessment, the Board does not recommend that shareholders vote for the election of Roaring Blue Lion's nominees - Ronald K. Tanemura and Charles W. Griege, Jr. - as we believe that their election would not be in the best interests of all shareholders...Our Board has a clear strategy for HomeStreet and the experience and expertise to execute it. The Company's highly-qualified nominees, Sandra A. Cavanaugh, Mark K. Mason and Donald R. Voss, are key members of our leadership team, have a strong track record of enhancing shareholder value and a deep understanding of HomeStreet's business."

09:08 EDT Nuvectra COO, CFO Walter Berger to resign - Nuvectra announced that Walter Berger has resigned as Nuvectra's COO and CFO to pursue another business opportunity, effective May 24. The board accepted Berger's resignation and has appointed Jennifer Kosharek, the company's current VP, controller and principal accounting officer, as interim CFO as it initiates a search for a successor. The company said, Berger's departure is not based on any disagreement with the company's accounting principles or practices, internal controls or financial statement disclosures. Kosharek joined Nuvectra in January 2016 as executive director, corporate controller, and was appointed VP, controller and principal accounting officer in June 2018. Kosharek has led the company's external financial reporting, corporate accounting, corporate internal controls, shared services, payroll and tax functions. Prior to joining Nuvectra, Kosharek was the corporate controller and subsequently served as the CFO and VP of finance at Interphase from 2011 to 2015.

09:07 EDT INmune Bio reports stock purchase agreement for up to $20M with Lincoln Park - INmune Bio announced a common stock purchase agreement with Lincoln Park Capital Fund a Chicago-based institutional investor for up to $20M, including an initial investment of $300,000. This investment by LPC is in addition to LPC's investment in INmune Bio's first round of funding in 2017, when INmune Bio was a private company. Subject to compliance with the transaction documents, INmune Bio will have the option but not the obligation to sell to LPC up to an additional $19.7M in shares of common stock over a 24-month period contingent and commencing upon the effectiveness of the resale registration statement and satisfaction of other conditions contained in the agreement. Proceeds from the sales will be used for general corporate purposes, including advancing the company's drug development pipeline. The company believes this funding option will help INmune Bio advance its drug development pipeline into Phase II clinical trials. "This financing agreement provides flexibility to opportunistically access capital at our option under favorable terms to advance our innate immune therapies in cancer and Alzheimer's disease," said David Moss, CFO of INmune Bio.

09:03 EDT Old Dominion announces new $350M stock repurchase program - Old Dominion Freight Line announced that its board has approved a new two-year stock repurchase program authorizing the repurchase of up to $350M of its outstanding common stock. This new repurchase program will commence upon the expiration of the current two-year repurchase program, which was announced on May 17, 2018. The remaining authorization under the current repurchase program was $48.5M as of May 15.

08:52 EDT Sony to buy back up to 60M shares under new repurchase authorization - In a regulatory filing, Sony disclosed that the company approved, at the meeting of its board of directors, the setting of parameters for repurchase of shares of its own common stock. The authorization allows for the repurchase of up to 60M shares for a maximum purchase price of up to Y200B from May 17, 2019 to March 31, 2020 via expected open market purchases through the Tokyo Stock Exchange based on a discretionary trading contract, according to the filing.

08:39 EDT Celgene receives EC approvals for REVLIMID-, IMNOVID-based combination regimens - Celgene Corporation announced that the European Commission has approved two new triplet regimens based on Celgene's proprietary IMiD treatments, REVLIMID and IMNOVID. REVLIMID in combination with bortezomib and dexamethasone, is now indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. In addition, IMNOVID, in combination with bortezomib and dexamethasone, is now indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. The approval for the REVLIMID triplet was supported by data from SWOG S07773, a phase 3 trial evaluating the triplet combination, RVd, in adult patients with previously untreated multiple myeloma. The approval of the IMNOVID triplet was supported by data from OPTIMISMM4, the first prospective phase 3 trial to evaluate an IMNOVID-based triplet regimen in patients who were all previously treated with REVLIMID, and the majority of patients were REVLIMID refractory. Results from OPTIMISMM were recently published in The Lancet Oncology. Pomalidomide in combination with bortezomib and dexamethasone is not approved for any use in the United States.Lenalidomide in combination with bortezomib and dexamethasone is not approved for any use in the United States.

08:35 EDT DILIsym Services announces FDA renewal of software licenses - DILIsym Services, a Simulations Plus company, announced that the U.S. Food and Drug Administration has renewed its multi-seat license for the company's flagship quantitative systems toxicology modeling software, DILIsym. The renewal provides DILIsym access to FDA employees across all FDA divisions. DILIsym prospectively supports key management decisions by providing information about potential drug-induced liver injury risk in upcoming experimental or clinical study designs, as well as mechanistic rationale for the underlying biochemical events that could cause liver toxicity.

08:22 EDT AstraZeneca to present long-term follow-up data on CALQUENCE at ASCO meeting - The company said, "AstraZeneca has established hematology as one of its key areas of focus. At the ASCO meeting and the upcoming 24th Congress of the European Hematology Association, the Company will present long-term trial follow-up data showing the promising response rate, duration of response and safety profile of the Bruton's tyrosine kinase inhibitor CALQUENCE in chronic lymphocytic leukemia, including: Three-year results from the Phase Ib/II ACE-CL-003 trial evaluating CALQUENCE and obinutuzumab in treatment-naive and previously-treated CLL. 19-month results from the Phase II ACE-CL-208 trial of CALQUENCE in patients with relapsed or refractory CLL intolerant to ibrutinib. These data are part of a robust development program that includes two pivotal clinical trials for CALQUENCE in CLL with data anticipated in 2019: the Phase III ASCEND trial in relapsed or refractory CLL, which recently met its primary endpoint, and the ongoing Phase III ELEVATE-TN trial evaluating CALQUENCE with and without obinutuzumab in 1st-line CLL."

08:20 EDT AstraZeneca to present new data from Phase III FLAURA trial at ASCO meeting - The company said, "New data from the Phase III FLAURA trial will explore clinical outcomes associated with the detection of epidermal growth factor receptor mutations in plasma at three or six weeks after starting treatment with TAGRISSO. With the presentation of the Phase II SAVANNAH trial design, AstraZeneca will explain how it will explore the combination of TAGRISSO and savolitinib to potentially overcome MET-driven EGFR tyrosine kinase inhibitor resistance following TAGRISSO treatment in EGFR-mutated NSCLC. Despite recent therapeutic progress, platinum-resistant ovarian cancer remains a therapeutic challenge. Results of a multicenter, double-blind Phase II trial conducted by the Princess Margaret, California, Chicago and Mayo Phase II Consortia will show for the first time increased OS data with the Wee-1 inhibitor adavosertib when associated with the antimetabolite therapy Gemcitabine."

08:19 EDT AstraZeneca to provide new longer-term survival data of IMFINZI at ASCO - The company said, "AstraZeneca made a significant breakthrough in the treatment of NSCLC beginning in 2017 with the Phase III PACIFIC trial demonstrating unprecedented PFS and subsequently OS benefits for patients with unresectable Stage III NSCLC treated with IMFINZI following concurrent chemoradiotherapy vs. standard of care. At this year's ASCO meeting, AstraZeneca will provide new longer-term survival evidence of IMFINZI with a three-year OS update. Sub-analysis presentations of Phase III data from SOLO-1, the only trial of a PARP inhibitor to demonstrate improvement in PFS for women with BRCAm advanced ovarian cancer as a 1st-line maintenance treatment, will reinforce the potential of using LYNPARZA earlier in the treatment pathway."

08:14 EDT AstraZeneca to present 93 abstracts spanning tumor types at ASCO meeting - AstraZeneca will present new research across an Oncology portfolio, including data for its transformational cancer medicines LYNPARZA and IMFINZIat the 2019 American Society of Clinical Oncology Annual Meeting. In all, the Company will present 93 abstracts spanning multiple tumor types, including 12 oral presentations with one plenary session and four late-breakers. Highlights include: Late-breaking results from the LYNPARZA POLO trial, the first positive Phase III trial of any PARP inhibitor in germline BRCA-mutated metastatic pancreatic cancer, a devastating diagnosis with critical unmet medical need. This is the first Phase III trial to validate a targeted treatment in a biomarker-selected population of pancreatic cancer. Results of the Phase III SOLO-3 trial highlighting the efficacy and safety for LYNPARZA monotherapy vs. standard-of-care chemotherapy in treating patients with gBRCAm advanced ovarian cancer who had two or more prior lines of treatment. This data underscores LYNPARZA's clinical benefit irrespective of line of therapy for women with BRCAm advanced ovarian cancer and the importance of knowing BRCA status at diagnosis. Three-year overall survival data from the Phase III PACIFIC trial providing new longer-term survival evidence for IMFINZI in unresectable, Stage III non-small cell lung cancer in patients whose disease had not progressed following chemoradiation therapy. IMFINZI is the only immunotherapy to have demonstrated significant OS benefits in this curative-intent setting, and these updated data reaffirm the PACIFIC regimen as a standard of care for these patients.

08:11 EDT Exelixis enters option and license agreement with Iconic Therapeutics - Exelixis announced that it has entered into an exclusive option and license agreement with Iconic Therapeutics. This collaboration reflects Exelixis' ongoing strategy to build a pipeline beyond its lead product, CABOMETYX, through both internal drug discovery and external business development. This agreement with Iconic is Exelixis' second strategic collaboration focused on novel biologics, following the company's collaboration with Invenra announced in May 2018. Under the terms of the agreement, Exelixis will gain an exclusive option to license ICON-2, Iconic's lead oncology ADC program, in exchange for an upfront option payment to Iconic of $7.5M and a commitment of preclinical development funding. Exelixis would exercise its option at the time of a potential IND application, and upon doing so would make an option exercise payment to Iconic and assume responsibilities for all subsequent clinical development and commercialization activities. Should Exelixis elect to exercise its option, Iconic will become eligible for future development, regulatory and commercialization milestone payments, as well as royalties on potential sales.

08:11 EDT CalAmp partners with Cryoport to develop shipping monitoring system - CalAmp (CAMP) announced a strategic collaboration with Cryoport (CYRX) to develop a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments. It is estimated that pharmaceutical products that require temperature controlled storage and transport are worth approximately $283B, and they are expected to rise 70% between 2015 and 2021. If successful, the combination of the Cryoport Express Shippers and the Cryoportal Logistics Management Platform, coupled with CalAmp's new-to-market SC iOn Tag Bluetooth sensor technology and SC iOn Command platform, would allow Cryoport to offer another advanced logistics solution that would pro-actively manage supply chain visibility across multi-mode global shipping routes.

08:10 EDT Charles River announces investment in Resero Analytics - Charles River Laboratories International announced that it has invested in Resero Analytics, a software company focused on providing solutions to the biopharmaceutical industry. As part of its investment, Charles River will collaborate with Resero Analytics and is now the exclusive contract research organization partner for TurboToxicology, a report generation tool that enables faster delivery of reports. TurboToxicology analyzes nonclinical data in Standard for Exchange of Nonclinical Data and other structured data formats, and conducts statistical analyses, applies proprietary algorithms, and displays study results via user interfaces. The tool then formats the data, in concert with the scientist's interpretation, to generate a complete written

08:08 EDT Clovis to present four abstracts featuring data for Rubraca at ASCO - Clovis Oncology announced that four abstracts featuring data for Rubraca and ongoing studies in multiple tumor types will be presented at the 2019 American Society of Clinical Oncology Annual Meeting taking place May 31 - June 4 in Chicago. The accepted abstracts summarize clinical trials in which Rubraca is being evaluated as a single agent and as combination therapy with nivolumab in a variety of solid tumor types including ovarian, prostate, biliary tract and endometrial cancers. These include additional genomic profiling data from TRITON2, and new data from extended follow up of patients in ARIEL3.

08:07 EDT Lockheed Martin teams with Rafael on SPICE guidance kits - Lockheed Martin and Rafael Advanced Defense Systems signed a teaming agreement to jointly develop, market, manufacture and support Rafael's Smart, Precise Impact and Cost-Effective guidance kits for U.S. sale. SPICE is a family of stand-off, autonomous, air-to-surface weapon systems that provide affordable precision in a GPS-denied environment.

08:06 EDT Senior Housing announces sale of 4 properties for $24.1M - Senior Housing announced that it has sold four properties for an aggregate sales price of $24.1M. The four properties include: A two-story, 15,647 square foot medical office building, or MOB, located at 9025 Grant Street in Thornton, CO. Three skilled nursing facilities located in Van Nuys, CA, LaSalette, CA and Thousand Oaks, CA, with a total of 276 units. The sales were part of SNH's previously announced disposition plan to sell up to $900M of assets in connection with the restructuring of its business arrangements with Five Star Senior Living.

08:02 EDT Masimo receives FDA clearance of Radius PPG - Masimo announced FDA 510(k) clearance of Radius PPG, a tetherless sensor solution powered by Masimo SET that represents a significant breakthrough in patient monitoring. Radius PPG eliminates the need for a cabled connection to a pulse oximetry monitor, allowing patients to move freely and comfortably while still being continuously monitored reliably and accurately. Via wireless connection, measurements are displayed on Masimo host devices or third-party multi-parameter monitors with integrated Masimo technology, making Radius PPG immediately available for approximately two million monitors around the world. Coupled with the proven benefits of Masimo SET Measure-through Motion and Low Perfusion pulse oximetry, Radius PPG is suited for use anywhere patients can benefit from mobility.

07:36 EDT Zai Lab announces China NMPA acceptance of ETX2514SUL clinical trial application - Zai Lab announced that the China National Medical Products Administration, or NMPA, has accepted the company's clinical trial application, or CTA, to allow for the initiation of a Phase 3 clinical trial to evaluate the safety and efficacy of ETX2514SUL, a fixed-dosed combination of a broad spectrum lactamase inhibitor with sulbactam, for the treatment of patients with pneumonia and blood stream infections caused by carbapenem-resistant A. baumannii.

07:34 EDT Par Technology announces $8.5M U.S. Navy contract - PAR Technology announced that the U.S. Navy has awarded its subsidiary, Rome Research Corporation, or RRC, a five-year $8.5M contract. RRC will provide 24/7/365 operation and maintenance support services at the Naval Computer and Telecommunications Area Master Station Detachment located in LaMoure, North Dakota.

07:32 EDT RiceBran appoints Todd Mitchell as CFO - RiceBran (RIBT) appointed Todd Mitchell to the position of CFO and Secretary effective July 1. Mitchell most recently served as CFO of Park City Group (PCYG). He will succeed Dennis Dykes, who informed the company he will be stepping down from those positions on June 30 to pursue other business opportunities. Dykes and the company have agreed that he will provide transition and other consulting services after his resignation becomes effective to assist the company and Mitchell. Mitchell will serve as Executive VP of the company beginning on May 28 and CFO and Secretary effective as of July 1. Prior to joining RiceBran Technologies, Mitchell served as CFO of Park City Group beginning in September of 2015.

07:20 EDT Cellect Biotechnology receives noncompliance notification from Nasdaq - Cellect Biotechnology has received notification from Nasdaq that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550 for continued listing on Nasdaq. Nasdaq Listing Rule 5550 requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810 provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the company's American depositary shares, or ADSs, for the 30 consecutive business days prior to the date of the notification letter from Nasdaq, the company no longer meets the minimum bid price requirement. The notification letter has no immediate effect on the listing or trading of the company's ADSs on Nasdaq and, at this time, the ADSs will continue to trade on Nasdaq. The notification letter provides that the company has 180 calendar days, or until November 11, to regain compliance with Nasdaq Listing Rule 5550. To regain compliance, the bid price of the company's ADSs must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the company does not regain compliance by November 11, an additional 180 days may be granted to regain compliance, so long as the company meets Nasdaq listing requirements and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period by effecting a reverse share split or adjusting the ADS ratio, if necessary. If the company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the company of its determination to delist the company's ADSs, at which point the company will have an opportunity to appeal the delisting determination to a hearings panel. The company intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split or adjusting the ADS ratio, to regain compliance with the minimum bid price requirement under the Nasdaq listing rules.

07:14 EDT Walmart CFO says currency to negatively affect Q2 sales by about $1B - In the company's Q1 earnings commentary, President and CEO Doug McMillon said Walmart now has about 2,450 stores in the U.S. with grocery pickup, which has enabled it to provide same-day grocery delivery in nearly 1,000 locations at quarter-end. McMillon commented "We've been mirroring our eCommerce inventory in the U.S. to enable free next-day delivery from Walmart.com. Earlier this week, we launched this service in the southwest and will ultimately cover about 75% of the country by the end of the year." McMillon says Walmart plans to bring premium meats to about 500 stores by early next year. He added that "we know we can do more" in the advertising space. CFO Brett Briggs said Walmart's Q1 results "put us in a good position to achieve full-year goals." He said Walmart is monitoring the tariff discussions and is hopeful that an agreement can be reached. "Although we face tougher sales comparisons in Q2 due to the timing of weather-related benefits last year, the underlying business is strong and the omni strategy is working," Briggs said. He added, "Similar to last quarter, currency will likely be a headwind in Q2. Based on current exchange rates, we estimate sales will be negatively affected by about $1 billion, higher than anticipated at the beginning of the year."

07:08 EDT Neuralstem announces issuance of new patent covering use of neural stem cells - Neuralstem announced the expansion of their intellectual property portfolio with the recent issuance of a newly published patent. U.S. Patent No. 10,286,010, entitled "Methods of Treating Neurodegenerative Conditions" was issued on May 14 by the United States Patent and Trademark Office. The patent covers the use of transplanted human neural stem cells for the treatment of neurodegeneration resulting from disease and injury.

07:02 EDT Concert Pharmaceuticals initiates new open label trial evaluating CTP-543 dosing - Concert Pharmaceuticals announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. Patients in the trial will be randomized to receive either 12 mg twice-daily or 24 mg once-daily of CTP-543 over a 24 week treatment period. This new dose regimen trial is designed to complement the first open label trial initiated by Concert in March 2019, which is ongoing in patients randomized to receive either 8 mg twice-daily or 16 mg once-daily of CTP-543 over a 24 week treatment period. These two trials are designed to inform on the optimal dosing regimen for CTP-543 for future clinical trials. The open label trial will enroll approximately 60 patients with moderate-to-severe alopecia areata in the United States and Canada. The trial will measure the relative change in Severity of Alopecia Tool score between Week 24 and baseline. The trial is expected to be completed in the first half of 2020. All patients who complete 24 weeks of treatment will be eligible to enroll into an open label extension study of CTP-543.

06:54 EDT Lannett begins marketing generic Adderall - Lannett announced that it has begun marketing a generic version of Adderall, an immediate-release, or IR, mixed salt of a single entity Amphetamine tablet product, with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg tablets. Adderall including generic versions have an estimated IQVIA market value of approximately $349M for the 12 months ending March, although actual generic market values are expected to be lower. As previously announced, Lannett entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of a generic version of Adderall IR. Under the agreement, Lannett primarily provides sales, marketing and distribution support for the product, for which it will receive a share of the profits.

06:53 EDT Colfax to sell Howden to KPS Capital Partners for $1.8B

06:47 EDT Zymeworks and GlaxoSmithKline expand Azymetric bispecific agreement - Zymeworks (ZYME) announced that GSK (GSK) has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas. Under the expanded agreement, GSK will now have access to Zymeworks' heavy-light chain pairing technology, part of its proprietary Azymetric platform. Zymeworks' Azymetric platform enables the development of bispecific and multifunctional therapeutics while maintaining the characteristics of naturally-occurring human antibodies. GSK will have the option to develop and commercialize bispecific drugs across different disease areas and Zymeworks will be eligible to receive increased preclinical, development and commercial milestone payments. If all six programs are developed and commercialized, the new potential value of the collaboration would be up to $1.1B. Additionally, Zymeworks is eligible to receive increased tiered royalties on worldwide sales.

06:41 EDT Essa Pharma to acquire Realm Therapeutics in stock transaction valued at $21.5M - Essa Pharma (EPIX) announced that it has entered into a definitive agreement with Realm Therapeutics (RLM) setting forth the terms of an acquisition whereby Essa will acquire all of the issued and outstanding shares of Realm in an all-stock transaction. The acquisition, subject inter alia to Realm Shareholder approval, is intended to be implemented by means of a United Kingdom Court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act 2006 and is expected to be completed by mid-year 2019. Upon the closing of the acquisition, the company will continue to operate as Essa Pharma, trade on Nasdaq and TSX-V Market and operate in the United States as Essa Pharmaceuticals, a Houston, Texas-registered wholly-owned subsidiary. The company will focus on advancing Essa's pipeline of novel potential treatments for prostate and other cancers. The terms of the acquisition value Realm's issued and outstanding shares at approximately $21.5M, which represents a 5% premium over Realm's estimated net cash amount of $20.5M at the closing of the acquisition. Under the terms of the acquisition, Realm shareholders will be entitled to receive approximately 0.058 Essa ordinary shares for each Realm Share based upon a 60-day volume-weighted average price of Essa shares of $3.19 per share of Essa as of the close of trading on May 14, subject to a final adjustment based on Realm's final net cash amount prior to closing of the acquisition. Upon the close of the Acquisition, Essa's current management team will continue to lead the company. In addition, it is expected that the company's board of directors will be increased to nine members of which three will be Realm-nominated candidates, with two current Essa directors resigning. The acquisition is intended to be implemented by means of a UK Court-sanctioned scheme of arrangement under Part 26 of the companies Act. The acquisition is conditional on, among other things: the approval of Realm shareholders at the court meeting and the passing of the resolutions by Realm shareholders at the general meeting and the sanction of the scheme by the UK court. The acquisition does not require the approval of Essa shareholders. The acquisition is expected to become effective by mid-year 2019, subject to the satisfaction of the conditions set out.

06:33 EDT Colfax to sell Air and Gas Handling business to KPS Capital Partners for $1.8B - Colfax announced that it has signed a definitive agreement to sell its Air and Gas Handling business to KPS Capital Partners for enterprise value of $1.8B, including $1.66B in cash consideration and $0.14B in assumed liabilities and minority interest, subject to customary closing adjustments. The Air & Gas Handling business had approximately $90M of segment operating profit and $200M of adjusted EBITDA in the twelve months ended March 29. Completion of the transaction is expected in the second half of 2019 and is subject to customary closing conditions and approvals. Colfax expects to report the Air & Gas Handling business as a discontinued operation in its future results.

06:16 EDT T. Rowe Price sold most of its shares in Tesla over first three months of year - T. Rowe Price Associates sold roughly 81% of its shares of Tesla over the first three months of the year, according to a regulatory filing. The fund manager held 1.7M Tesla shares as of March 31, down from 8.9M shares at the end of 2018, according to the filing.

06:07 EDT Intec Pharma enters agreement with Merck to explore Accordion Pill platform use - Intec Pharma (NTEC) announced it has entered into an agreement with Merck (MRK) to explore using the Accordion Pill platform for an undisclosed development program. "We are very excited to collaborate with Merck," said Jeffrey Meckler, CEO of Intec Pharma. "Through partnerships such as this, we continue to evaluate how the Accordion Pill's innovative gastric retention and controlled drug release properties may be used to enhance therapeutic attributes. We believe this program, as well as our ongoing collaboration with Novartis, paves the way for other new collaborations to further validate the AP platform and confirms our technical abilities to build custom APs. Importantly, these new programs offer the opportunity to pursue novel additions to our product and intellectual property portfolio."

06:04 EDT Thermo Fisher to acquire Cork, Ireland manufacturing site from GSK for EUR 90M - Thermo Fisher Scientific (TMO) announced that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline (GSK) for approximately EUR 90M in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs). This announcement follows the recently completed acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies. Thermo Fisher is also investing $150M to expand its sterile fill-finish sites in Monza and Ferentino, Italy, and Greenville, North Carolina, and plans to complete the previously announced $50M expansion of its St. Louis, Missouri, biologics facility later this year. The GSK transaction, which is expected to be completed by the end of 2019, is subject to customary closing conditions, including regulatory approvals. Upon completion, the site will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services Segment.

06:01 EDT Telefonica, Amdocs announce multi-year extension, expansion of partnership - Amdocs (DOX) and Telefonica (TEF) announced a multi-year extension and expansion of their strategic partnership. The partnership will help advance the operator's digital transformation initiatives in Argentina and Chile with an expanded portfolio of support services designed to accelerate Telefonica's digitalization and modernization journey.

05:47 EDT Orion Group announces contract award of about $13M - Orion Group announced a contract award of approximately $13M. The company's concrete segment, TAS Commercial Concrete Construction, or TAS, was recently awarded a contract for a 745,000 square foot residential tower in Houston, Texas. TAS is performing the concrete foundation work and topping slabs as well as providing cast-in-place concrete for the multi-level building, which recently commenced construction and is due to be completed in Q1 of 2020.

05:38 EDT Roche says entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions - Roche announced "positive data" from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adolescents with recurrent or refractory solid tumours with and without neurotrophic tyrosine receptor kinase, or NTRK, ROS1 or anaplastic lymphoma kinase, or ALK, gene fusions. The study showed entrectinib shrank tumours in all children and adolescents who had NTRK, ROS1 or ALK fusion-positive solid tumours, including two patients achieving a complete response. Of the 11 patients, five patients with primary high-grade tumours in the central nervous system, or CNS, had an objective response, including one patient with a complete response. The safety profile of entrectinib was consistent with that seen in previous analyses. Data will be presented at the American Society of Clinical Oncology Annual Meeting.

05:32 EDT Arconic, USW extend labor agreements to continue talks - The United Steelworkers said that contract negotiations with Arconic have stalled, hours before the existing labor agreements are set to expire and with management demanding economic and non-economic concessions that the union has dismissed as excessive and unnecessary. The union and company have agreed that USW members at Arconic will continue working under the terms and conditions of their existing agreements while bargaining continues. USW International Vice President Tom Conway, who chairs the negotiations, said that the proposals currently on the table from Arconic contain concessions both too broad and too deep for USW members and their families to absorb.